Read more

November 01, 2019
2 min read
Save

New PresbyLASIK algorithms show satisfactory outcomes

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Hyperopic and presbyopic treatment with the Technolas Teneo excimer laser from Bausch + Lomb, using two different algorithms in the dominant and nondominant eyes, showed safety, efficacy and stability at 24 months.

Perspective from Brandon Baartman, MD

Eighty eyes of 40 patients were included in the retrospective study. After creating a flap with the VisuMax femtosecond laser system (Carl Zeiss Meditec), excimer laser treatment was performed using the Proscan algorithm for the distance dominant eye (target at 0 D, optical zone at 6.5 mm and nomogram at 100%) and the Supracor algorithm for the near dominant eye (target from 0 D to –0.5 D, optical zone at 6 mm and nomogram at 117%).

The treatment showed high efficacy, with 93% of the eyes achieving 20/20 or better binocular uncorrected distance visual acuity and 90% achieving J1.5 or better binocular uncorrected near visual acuity.

Regarding safety, at 24 months, approximately 18% of dominant eyes had no change in corrected distance visual acuity and approximately 83% gained one line. A loss of one line was reported in 50% of nondominant eyes. In terms of stability, a slight regression occurred between months 3 and 24, likely due to epithelium cellular changes. A change of +0.22 D was reported for the nondominant eye, and a change of +0.39 D was reported for the dominant eye.

“Refractive surgery for presbyopia has been one of the most discussed subjects in refractive ophthalmology,” the authors wrote. “Proscan surgery in the dominant eye and Supracor in the nondominant eye using the Teneo 317 algorithm demonstrated that the hyperopic presbyopic excimer laser surgery technique outcomes are reasonable after 24 months of follow-up.” by Michela Cimberle

Disclosures: The authors report no relevant financial disclosures.